A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes

Abstract

Our results suggest the presence of EGFR wild-type, KRAS gene mutations or squamous cell carcinoma were associated with high PD-L1expression, which provides potential benefited population for the administration of PD-1/PD-L1 blockade in human lung cancer.